Evidence map›Paper›PMID 26965440›Full record

Trial reportLeukemia2016

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.

T Büchner, U O Krug, R Peter Gale, A Heinecke, M C Sauerland, C Haferlach, S Schnittger, T Haferlach, C Müller-Tidow, M Stelljes and 19 more

Abstract readLetterRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

T BüchnerDepartment of Medicine A, Hematology, Oncology and Pneumology, University of Münster, Münster, Germany.
U O KrugDepartment of Hematology and Oncology, Klinikum Leverkusen; Leverkusen, Germany.
R Peter GaleDivision of Experimental Medicine, Department of Medicine, Haematology Research Centre, Imperial College London, London, UK.
A HeineckeInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
M C SauerlandInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
C HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
S SchnittgerMLL Munich Leukemia Laboratory, Munich, Germany.
T HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
C Müller-TidowDepartment of Medicine A, Hematology, Oncology and Pneumology, University of Münster, Münster, Germany.
M StelljesDepartment of Medicine A, Hematology, Oncology and Pneumology, University of Münster, Münster, Germany.
R M MestersDepartment of Medicine A, Hematology, Oncology and Pneumology, University of Münster, Münster, Germany.
H L ServeDepartment of Hematology and Oncology, University of Frankfurt, Germany.
J BraessDepartment of Hematology and Oncology, Krankenhaus Barmherzige Brüder, Regensburg, Germany.
K SpiekermannDepartment of Internal Medicine III, University Hospital Munich, Grosshadern, Munich, Germany.
P StaibDepartment of Hematology and Oncology, St -Antonius Hospital, Eschweiler, Germany.
A GrüneisenDepartment of Hematology and Oncology, Vivantes Clinic Neukölln, Berlin, Germany.
A ReichleDepartment of Hematology and Oncology, University Regensburg, Regensburg, Germany.
L BalleisenDepartment of Hematology and Oncology, Evangelisches Krankenhaus, Hamm, Germany.
H EimermacherDepartment of Hematology and Oncology, KKH St Marien Hospital, Hagen, Germany.
A GiagounidisMarienhospital Düsseldorf, Clinic for Oncology, Hematology and Palliative Care, Düsseldorf, Germany.
H RascheDepartment of Hematology and Oncology, Klinikum Bremen-Mitte, Bremen, Germany.
E LengfelderDepartment of Hematology and Oncology, University of Heidelberg, Mannheim, Germany.
D GörlichInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
A FaldumInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
W KöpckeInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
R HehlmannDepartment of Hematology and Oncology, University of Heidelberg, Mannheim, Germany.
B J WörmannGerman Society of Hematology and Oncology, Berlin, Germany.
W E BerdelDepartment of Medicine A, Hematology, Oncology and Pneumology, University of Münster, Münster, Germany.
W HiddemannDepartment of Internal Medicine III, University Hospital Munich, Grosshadern, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Age FactorsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaleMiddle AgedPrognosisRisk FactorsTreatment OutcomeYoung Adult

Identifiers

PMID26965440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.